Altamira Therapeutics Ltd. has entered into a collaboration agreement with Univercells SA to evaluate the use of the company’s proprietary Semaphore platform for the delivery of mRNA vaccines.
Researchers from Foghorn Therapeutics Inc. recently presented preclinical data for FHD-609, a heterobifunctional degrader of BRD9 designed for the treatment of sarcoma. Synthesis and optimization of a series of first-generation compounds led to the identification of FHD-609 as a rapid, selective and highly potent BRD9 degrader, with high plasma stability and acceptable solubility.
Scientists at China Resources Shenzhen Bay Development Co. Ltd., National Institutes of Pharmaceutical Research & Development, and Research Institute of Tsinghua University in Shenzhen have described macrocyclic compounds acting as ALK tyrosine kinase receptor and/or ALK tyrosine kinase receptor (mutant) inhibitors reported to be useful for the treatment of malignant neoplasms.
Pannex Therapeutics Inc. has divulged pannexin-1 (PANX1; MRS1) inhibitors reported to be useful for the treatment of neuropathic pain and opioid dependency.
Brise Pharmaceutical (Shanghai) Co. Ltd. has identified calcitonin gene-related peptide (CGRP) receptor antagonists reported to be useful for treatment of cerebrovascular and vascular disorders.
The US Department of Veterans Affairs has synthesized substituted aminopiperazine compounds reported to be useful for the treatment of bacterial and fungal infections.
Nurexone Biologic Inc. has signed a strategic service agreement with Vivox Ltd. for large-scale animal testing of Exopten therapy for spinal cord injury (SCI).
To address the need for novel therapeutic candidates against Duchenne muscular dystrophy (DMD), investigators at Mitorx Therapeutics Ltd. developed a library of novel small-molecule mitochondriotropic agents.
Galectin-3 (Gal-3) is used as a marker of activated microglia, and thus a protein that drives inflammation. Patients with Alzheimer’s disease (AD) have shown increased levels of Gal-3 in their cerebrospinal fluid (CSF) compared to healthy controls, as well as increased expression in their brain tissue.